AlzeCure Pharma
STOCKHOLM, SE / ACCESSWIRE / August 30, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer's disease.
The MAD Phase I study is AlzeCure's third clinical study with ACD856, the lead candidate drug within the company's NeuroRestore platform. ACD856 is being developed as a symptom-relieving treatment for disease states where the cognitive ability is impaired, such as in Alzheimer's disease. The primary study goal is to evaluate ACD856's tolerability and safety after repeated dosing, as well as to examine early signals on brain activity.
The substances in the NeuroRestore platform stimulate several important signaling pathways in the brain, which, among other things, leads to improved cognition. Preclinical studies have shown that AlzeCure's candidate drugs strengthen the communication between nerve cells and improve cognitive ability including memory functions.
"I'm very pleased that we have all regulatory approvals in place to be able to start the next study with ACD856. This means we will be able to start the MAD study during the fall, which is in line with our previously communicated goals," said Johan Sandin, CSO at AlzeCure Pharma.
"This is a statement of strength that shows that AlzeCure continues to deliver according to plan," said Martin Jönsson, CEO of AlzeCure Pharma AB. "Diseases with cognitive disorders, and especially Alzheimer's disease, are areas with high need of new, more effective treatments and I am very much looking forward to the continued development of this important candidate drug".AlzeCure Pharma will give a strategic update on Alzheimer's disease and the NeuroRestore platform on September 1 at 9 a.m. CET at Redeye. Watch the livestream via: https://www.redeye.se/events/816325/strategy-update-alzecure-pharma-2.
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser., For more information, please visit www.alzecurepharma.se .
About NeuroRestore
NeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive ability is impaired, e.g. Alzheimer's Disease, sleep apnea, traumatic brain injury and Parkinson's disease. NeuroRestore stimulates several important signaling pathways in the brain, which among other things leads to improved cognition. In preclinical studies with NeuroRestore we have been able to show that our drug candidates enhance communication between the nerve cells and improve cognitive ability. NeuroRestore stimulates specific signaling pathways in the central nervous system known as neurotrophins, the most well-known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). The levels of NGF and BDNF are disturbed in several disease states and the signaling is reduced. The impaired function impairs communication between the synapses, i.e. the contact surfaces of the nerve endings, as well as reducing the possibility of survival for the nerve cells, which gives rise to the cognitive impairments. Neurotrophins play a crucial role for the function of nerve cells, and a disturbed function of BDNF has a strong genetic link to impaired cognitive ability in several different diseases, such as Alzheimer's, Parkinson's disease, traumatic brain injury and sleep disorders. There is also a link between BDNF signaling and depression, something that has been further strengthened in recent years.
About Alzheimer's disease
Alzheimer's disease is the most common form of dementia, affecting approximately 45 million people worldwide. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about 1,000 billion USD globally in 2018. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute. The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than $10 billion in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about SEK 63 billion yearly, which is more than for cancer and cardiovascular diseases combined.
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure's Alzheimer's project receives approval to start next clinical phase I study with ACD856
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/661943/AlzeCures-Alzheimers-Project-Receives-Approval-to-start-Next-Clinical-Phase-I-Study-with-ACD856
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Graid Technology Announces Strategic License Agreement With Intel Corporation to Accelerate RAID Innovation14.10.2025 18:00:00 CEST | Press release
SANTA CLARA, CALIFORNIA / ACCESS Newswire / October 14, 2025 / Graid Technology announced an agreement with Intel Corporation to enter into a license agreement granting Graid Technology the rights to develop, market, sell, and support Intel® Virtual RAID on CPU (Intel® VROC) globally. This strategic agreement is expected to accelerate innovation in the enterprise RAID market and deliver transformative outcomes for data center customers worldwide.Graid Technology and Intel Announce Strategic License Agreement In today's digital economy, data is the most valuable asset for every organization, and ensuring it is both resilient and readily available is critical to unlocking its full value. Through this agreement, Graid Technology will combine the proven enterprise performance of Intel® VROC with the breakthrough innovation of its own SupremeRAID™ portfolio, the industry's first GPU-based RAID architecture for high-performance workloads such as AI and HPC. By bringing together CPU-based and
GA-ASI and Hanwha Finalize Deal To Produce Gray Eagle(R) STOL UAS14.10.2025 17:00:00 CEST | Press release
Partnership Will Enable Cost Savings By Manufacturing Unique and Flexible UAS Platform in South Korea SAN DIEGO, CA / ACCESS Newswire / October 14, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and South Korea industry leader Hanwha Aerospace signed an agreement on October 14 to partner in development of the Gray Eagle® Short Takeoff and Landing (GE STOL) unmanned aircraft system (UAS). This landmark agreement marks the beginning of a new phase in U.S.-Korea defense cooperation, extending beyond traditional alliance structures to deliver next-generation, runway-independent UAS solutions that maximize commanders' options in the face of evolving mission demands. The deal marks the beginning of a co-development and co-production program between GA-ASI and Hanwha, with work set to begin immediately. The GE STOL will be offered to a worldwide customer base, including South Korea Ministry of Defense and the United States War Department. Under the agreement, the two companies wil
Polaris Renewable Energy Announces New Credit Facility, Executive Enhancements & Q3-25 Earnings Conference Call14.10.2025 13:50:00 CEST | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 14, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce that it has entered into a US$3.5 Million Working Capital & a US$10.0 Million Letter of Credit Facility (the Facility) with the Canadian Imperial Bank of Commerce (CIBC) and the Export Development Canada (EDC). The Facility will enhance Polaris' liquidity as it continues to work towards growing its current footprint in Latin America and the Caribbean. CIBC has been the lead Banker for Polaris in Canada since 2015, while the EDC has also supported the Company in the past with similar facilities. The Company is also pleased to announce changes to its Named Executive Officers effective October 9th, as follows: Anton Jelic, CFO of the Company since December 2018 will be moving to a new role as Chief Administrative Officer to focus on Polaris' continuing growth in such key areas as IT, AI, Human Resources, Risk and continuing to strengthen Corpo
From Manual to Autonomous: Agentic CMS Automates Governance, Compliance, and Content Maintenance14.10.2025 09:00:00 CEST | Press release
Kontent.ai unveils the first CMS built for the AI era - automating governance, compliance, translations, and large-scale updates so teams can focus on creativity and growth. BRNO, CZ / ACCESS Newswire / October 14, 2025 / Across industries, marketing and content teams are being asked to achieve more with fewer resources. Yet expectations for faster publishing, more content and consistency keep rising.AI Agent reviewing thousands of content items AI Agent reviewing entire content repository for specific terms Under that pressure, generative AI has burst onto the scene, reshaping how content is created and discovered. Large language models (LLMs) and generative search experiences are redefining what customers see, hear, and believe about brands. But without structure and governance, AI can easily create more noise than value by diluting tone and introducing compliance risks. Agentic CMS was created to solve this tension. As the world's first agentic content management system, Kontent.ai'
Padcom and General Holdings Sign Term Sheet for USD 55 Million Structured Investment13.10.2025 15:00:00 CEST | Press release
RUSSELL, MB AND DUBAI, UAE, NY / ACCESS Newswire / October 13, 2025 / Potash and Agri Development Corporation of Manitoba Ltd. ("Padcom") and General Holdings Limited ("General Holdings"), a Dubai International Financial Centre (DIFC)-based private investment platform, are pleased to announce the signing of a US$55 million structured investment term sheet. The transaction outlines Padcom's next stage of expansion and General Holdings' continued focus on sustainable industrial and resource-linked investments. The transaction was originated by North Mountain Capital, which introduced the opportunity to General Holdings. Under the term sheet, General Holdings proposes to invest US$18.25 million as a Senior Secured Loan (Tranche 1) and US$36.75 million as Series A Preferred Equity (Tranche 2), with full warrant coverage. The proceeds will be used to expand Padcom's production capacity to 250,000 tonnes per annum of potash and related products, with an intended public listing targeted withi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom